Published June 30, 2023 | Version v1
Other Open

Oxamniquine derivatives overcome praziquantel treatment limitations for schistosomiasis

  • 1. The University of Texas Health Science Center at San Antonio
  • 2. The University of Texas at San Antonio

Description

Human schistosomiasis is a neglected tropical disease caused by S. mansoni, S. haematobium, and S. japonicum. Praziquantel (PZQ) is the method of choice for treatment. Due to constant selection pressure, there is an urgent need for new therapies for schistosomiasis. Previous treatment of S. mansoni included the use of Oxamniquine (OXA), a drug that activated by schistosomes' sulfotransferase (SULT). Guided by data from Xray crystallography and Schistosoma killing assays more than 350 OXA derivatives were designed, synthesized, and tested. We were able to identify CIDD-0150610 and CIDD-0150303 as powerful derivatives in vitro that kill (100%) of all three Schistosoma species at a final concentration of 143 µM. We evaluated the efficacy of the best OXA derivates in an in vivo model after treatment with a single dose of 100 mg/kg by oral gavage. The highest rate of worm burden reduction was achieved by CIDD -150303 (81.8%) against S. mansoni, CIDD-0149830 (80.2%) against S. haematobium and CIDD-066790 (86.7%) against S. japonicum. We have also evaluated the derivatives ability to kill immature stages since PZQ does not kill immature schistosomes. CIDD-0150303 demonstrated (100%) of killing for all life stages at a final concentration of 143 µM in vitro and effective reduction in worm burden in vivo. To understand how OXA derivatives fit in the SULT binding pocket, X-ray crystal structures of CIDD-0150303 and CIDD-0150610 demonstrate that the SULT active site will accommodate further modifications to our most active compounds as we tune them to increase favorable pharmacokinetic properties. Treatment with a single dose of 100 mg/kg by oral gavage of each PZQ and CIDD-0150303 reduced the worm burden in an animal model by (90.8%). Therefore, we conclude that CIDD-0150303, CIDD-0149830 and CIDD-066790 are the novel drugs that overcome OXA limitation, and CIDD-0150303 can be used with PZQ in combination therapy. 

Notes

Funding provided by: National Institute of General Medical Sciences
Crossref Funder Registry ID: http://dx.doi.org/10.13039/100000057
Award Number: 2k12GM111726

Funding provided by: National Institute of Allergy and Infectious Diseases
Crossref Funder Registry ID: http://dx.doi.org/10.13039/100000060
Award Number: AI27219

Funding provided by: National Institutes of Health
Crossref Funder Registry ID: http://dx.doi.org/10.13039/100000002
Award Number: P30 CA054174

Funding provided by: NIH-ORIP SIG Grant *
Crossref Funder Registry ID:
Award Number: S10OD030374

Funding provided by: National Institute of General Medical Sciences
Crossref Funder Registry ID: http://dx.doi.org/10.13039/100000057
Award Number: P30 GM124165

Funding provided by: NIH-ORIP HEI *
Crossref Funder Registry ID:
Award Number: S10OD021527

Files

S1_PDB_validation_report.pdf

Files (1.7 MB)

Name Size Download all
md5:ffd619744271dd65d8c471d4c4ff3bdb
1.3 MB Preview Download
md5:4e943ccd82e50eac6a4e7ab83ca849a8
28.8 kB Download
md5:f0aa713ec3819447eecb3107c84f120d
138.4 kB Download
md5:462d97d805c524bb13b11ee72f26338a
62.8 kB Download
md5:38fb4a1451d6622a3f16403b916f0c15
128.4 kB Download
md5:d06a5e8364395377c1111392765cd7ef
96.0 kB Download

Additional details

Related works

Is derived from
10.5061/dryad.wh70rxwrw (DOI)